SAJA Pharmaceuticals, in alignment with the Kingdom Vision 2030, has a new mission to make medicine accessible for all and ensure community reach to diversified therapeutic areas including critical care products serving hospital patients and life-threatening diseases.

Simultaneously with this direction, SAJA has entered into a new strategic collaboration with Xellia Pharmaceuticals to launch its first Critical care brands that will serve a wide range of infectious diseases.

Xellia Pharmaceuticals is a global specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Xellia Pharmaceuticals has five state-of-the-art manufacturing facilities located in; Denmark, Hungary, China, and in the U.S.

The contract was signed between Dr. Mohammed Khalil “CEO of SAJA” and Mr. Daniel Schwartzlose “President of Xellia’s International Business Unit”

The contract will strengthen SAJA’s position in the regional markets, as well as it will facilitate its vision to expand in the international pharmaceutical markets, and both companies shall be allies in fighting life-threatening infections.

The aim of this initiative by SAJA pharmaceuticals is to support the national transformation driven by the 2030 vision to nationalize the pharmaceutical industry and heavily contribute to the Kingdom’s drug availability goals